Mexican health regulators have approved a consumer campaign for the drug there, he said.

“Signs of Life”

Latisse is “finally showing some signs of life,” said Amit Hazan, an analyst who follows Allergan for New York investment bank Gleacher & Co., in a report on a survey he did with dermatologists.

Doctors that Hazan said he surveyed wrote an average of 39 prescriptions for Latisse, up 11% from a year earlier.

On Allergan’s call, Pyott suggested analysts should “stick to our guidance.”

“Don’t get too enthusiastic,” he said. “We’re happy this quarter finally was a good one after some disappointing ones, frankly.”

Allergan has projected full-year Latisse sales to come in at $100 million.

Latisse came about after Allergan found that bimatoprost, the active ingredient of its Lumigan glaucoma treatment, grew eyelashes.

Company officials have been high on the drug and what it could mean for the company.

Back when Latisse was released, Pyott said he expected it could do well because it was relatively inexpensive.

Allergan had projected Latisse’s average cost to a patient at $120, compared to $450 to $500 for Botox injections for wrinkles and $600 or more for injections of lower face wrinkle filler Juvéderm.

Latisse also is expected to draw customers to Allergan as young as in their late teens, compared to Botox’ 35 and older cosmetic customers, according to Pyott.

“This is a great traffic builder for” cosmetic surgeons, he said.